Intuitive Surgical Stock Just Fell Despite a 22% Revenue Jump. Here's What Investors Are Missing.

Impact · against what's priced in

The reported 22% revenue jump and 15% procedure growth for Intuitive Surgical are essentially non-events for the stock price, as they align closely with current market assumptions of 13.5-15.5% procedure growth. While the article argues the recurring revenue model provides a moat against Medtronic and J&J, the market has already priced in this structural incumbency.

JNJ+0.00: Doesn't touch the price's assumptions
The price assumes: OTTAVA surgical robot approval and launch

Intuitive Surgical Stock Just Fell Despite a 22% Revenue Jump. Here's What Investors Are Missing.

What matters in this story

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Intuitive Surgical Stock Just Fell Despite a 22% Revenue Jump. Here's What Investors Are Missing.

What matters in this story

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

How each ticker is affected

Connected tickers

Track these names every morning.

TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients

GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging

AstraZeneca: 3 Key Takeaways for Long-Term Investors

4 Blue-Chip Dividend Stocks That Kept Raising Payouts Through 2008 and 2020

Intuitive Surgical Stock Just Fell Despite a 22% Revenue Jump. Here's What Investors Are Missing.

What matters in this story

Next reads from the same story arc

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Intuitive Surgical Stock Just Fell Despite a 22% Revenue Jump. Here's What Investors Are Missing.

What matters in this story

Next reads from the same story arc

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

How each ticker is affected

Connected tickers

Track these names every morning.

TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients

GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging

AstraZeneca: 3 Key Takeaways for Long-Term Investors

4 Blue-Chip Dividend Stocks That Kept Raising Payouts Through 2008 and 2020